Research programme: neurofibromatosis type 1 therapies - PTC Therapeutics
Latest Information Update: 02 Oct 2006
At a glance
- Originator PTC Therapeutics
- Class Antineoplastics
- Mechanism of Action Protein synthesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neurofibromatosis 1
Most Recent Events
- 02 Oct 2006 Discontinued - Preclinical for Neurofibromatosis 1 in USA (unspecified route)
- 29 Apr 2003 Preclinical trials in Neurofibromatosis 1 in USA (unspecified route)